Pharmacokinetic Study of Perioperative Intravenous Ifosfamide

The use of cancer chemotherapy and hyperthermia as part of a surgical procedure in the management of patients with peritoneal carcinomatosis has gained prominence in recent years with selected patients showing benefit. Patients with peritoneal surface malignancy following cancer resection were treated with intraperitoneal hyperthermic (41.5–42.5°C) cisplatin and doxorubicin combined with the infusion of systemic ifosfamide chemotherapy. The concentrations of ifosfamide and 4-hydroxyifosfamide were determined in plasma, peritoneal fluid, urine, and when possible, within small tumor nodules less than 1 cm. Plasma concentrations of ifosfamide exceeded peritoneal fluid levels of ifosfamide during the 90 minutes of chemotherapy infusion. Both ifosfamide and 4-hydroxyifosfamide could be recovered from peritoneal tumor nodules throughout the 90 minutes of ifosfamide continuous infusion and exceeded plasma concentrations. 4-Hydroxyifosfamide within peritoneal surface cancer nodules suggested a favorable pharmacologic endpoint in the study of ifosfamide administered in the operating room.

[1]  P. Sugarbaker,et al.  Pharmacology of perioperative 5‐Fluorouracil , 2010, Journal of surgical oncology.

[2]  D. Elias,et al.  Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Esquivel Technology of Hyperthermic Intraperitoneal Chemotherapy in the United States, Europe, China, Japan, and Korea , 2009, Cancer journal.

[4]  B. Moran,et al.  Morbidity and Mortality With Cytoreductive Surgery and Intraperitoneal Chemotherapy: The Importance of a Learning Curve , 2009, Cancer journal.

[5]  D. Elias,et al.  Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Colombo,et al.  Combined treatment with local thermo-chemotherapy for non muscle invasive bladder cancer. The present role in the light of acquired data and preliminary cumulative clinical experiences. , 2008, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.

[7]  F. Zoetmulder,et al.  Learning curve of combined modality treatment in peritoneal surface disease , 2007, The British journal of surgery.

[8]  P. Sugarbaker Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy , 2007, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[9]  H. Schlitt,et al.  Continuous peritoneal perfusion: techniques, methods and applications. , 2007, Cancer treatment and research.

[10]  J. Esquivel,et al.  Prospective Morbidity and Mortality Assessment of Cytoreductive Surgery Plus Perioperative Intraperitoneal Chemotherapy To Treat Peritoneal Dissemination of Appendiceal Mucinous Malignancy , 2006, Annals of Surgical Oncology.

[11]  Harm H. Kampinga,et al.  Cell biological effects of hyperthermia alone or combined with radiation or drugs: A short introduction to newcomers in the field , 2006, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[12]  J. Lepock How do cells respond to their thermal environment? , 2005, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[13]  D. Dormont,et al.  First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in Stage IIIc ovarian epithelial cancer. , 2004, European journal of gynaecological oncology.

[14]  R. Issels,et al.  Ifosfamide with Regional Hyperthermia in Soft-Tissue Sarcomas , 2003, Oncology.

[15]  A. Lowy,et al.  Technology of intraperitoneal chemotherapy administration: a survey of techniques with a review of morbidity and mortality. , 2003, Surgical oncology clinics of North America.

[16]  R. Sticca,et al.  Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. , 2003, Surgical oncology clinics of North America.

[17]  J. Pignon,et al.  Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  H. Groen,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Ifosfamide and its Metabolites , 2001, Clinical Pharmacokinetics.

[19]  Y. Nishimura,et al.  For the clinical application of thermochemotherapy given at mild temperatures. , 1999, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[20]  B. Schem,et al.  Status of clinical hyperthermia. , 1999, Acta oncologica.

[21]  H. Keizer,et al.  High-performance liquid chromatographic determination of stabilized 4-hydroxyifosfamide in human plasma and erythrocytes. , 1998, Journal of chromatography. B, Biomedical sciences and applications.

[22]  P. Sugarbaker,et al.  Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model , 1997, Cancer Chemotherapy and Pharmacology.

[23]  P. Sugarbaker,et al.  Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy , 1996, Cancer.

[24]  B. Teicher,et al.  Hyperthermia and platinum complexes: time between treatments and synergy in vitro and in vivo. , 1995, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[25]  K. Jablonski,et al.  Prognostic Features of 51 Colorectal and 130 Appendiceal Cancer Patients with Peritoneal Carcinomatosis Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy , 1995, Annals of surgery.

[26]  J G McVie,et al.  Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. , 1990, Cancer chemotherapy and pharmacology.

[27]  P. Wilkinson,et al.  A simple quantitative HPLC assay for ifosfamide in biological fluids. , 1986, Biomedical chromatography : BMC.

[28]  B. Barlogie,et al.  In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. , 1980, Cancer research.

[29]  G. Hahn,et al.  Thermochemotherapy: synergism between hyperthermia (42-43 degrees) and adriamycin (of bleomycin) in mammalian cell inactivation. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[30]  G. Hahn,et al.  Thermochemotherapy: Synergism Between Hyperthermia (42-430) and Adriamycin (or Bleomycin) in Mammalian Cell Inactivation , 2022 .